Filter
1772
Text search:
Interval
Featured
190
484
Language
Document type
985
320
292
73
45
24
20
5
3
2
2
1
Countries
144
74
47
46
44
41
38
34
34
30
30
30
28
28
27
25
23
23
20
19
19
17
16
14
13
13
11
11
10
10
10
9
9
8
8
7
7
7
6
6
5
5
5
5
5
4
4
4
4
4
4
4
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
734
215
112
89
54
22
20
1
Toolboxes
158
136
130
75
60
56
46
44
35
32
31
29
29
26
23
21
14
13
13
11
11
9
9
4
2
N Engl J Med 2019;380:2429-39.DOI: 10.1056/NEJMoa1901113
6 June 2022
These WHO interim recommendations on the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
Th
...
31 March 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
Vaccines are a critical tool in the battl
...
29 Dec 2021. Comprehensive slideset updated regularly to include the latest data and guidance on best practices for COVID-19 diagnosis and prevention of COVID-19 transmission.
These are standing orders for eligible nurses and healthcare professionals to administer the Moderna COVID-19 vaccine to persons 18 years of age and older
Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat
...
The paper provides the rationale for these recommendations, which are based on analyses of data from the TRACT trial.
24 May 2021; Guidance for vaccinators on how to store, prepare, draw up and administer COVID-19 vaccines Updated May 2021 · Western Cape Edition
Practical Approach to Care Kit: Vaccine
Health care and social service systems are facing exceptional demands at this time. Evidence is emerging that the COVID-19 pandemic is disproportionately impacting low-income neighborhoods, communities of color, immigrant and other economically and medically vulnerable patients. These are the patien
...
Training on handling, storing and transporting Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran)
recommended
4 August 2021. Currently, Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran) is the only COVID-19 vaccine that should be stored and transported at -60ºC to -86ºC ultra-low temperature (ULT) conditions. Prior to use the vaccine can be transferred to -20ºC freezer or +2-8ºC refrigerator at
...
The Lancet Published Online
October 8, 2021 https://doi.org/10.1016/ S0140-6736(21)02143-7
Vaccination programmes against COVID-19 and seasonal influenza are currently being implemented in parallel in many countries. Administration of both vaccines during the same visit has potential advantages. This document presents the evidence related to coadministration of Covid-19 and influenza vacc
...
This summary covers the preventive approach to breast cancer control and includes prophylactic medications, prophylactic surgery and lifestyle modifications for breast cancer prevention. Health professional training and individual risk assessments and counseling are also discussed.
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been
...
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Th
...
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
The COVID-19 Vaccine (Whole Virion Inactivated) BBV152, COVAXIN® vaccine explainer includes key information on the vaccine specific requirements.
Lancet Public health 2022 January 6, 2022 https://doi.org/10.1016/ S2468-2667(21)00249-8
Growth in the number of individuals living with dementia underscores the need for public health planning efforts and policy to address the needs of this group. Country-level estimates can be used to inform nati
...
